Bulletin
Investor Alert

press release

April 27, 2022, 7:00 a.m. EDT

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

WATERTOWN, Apr 27, 2022 (GLOBE NEWSWIRE via COMTEX) -- WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. /zigman2/quotes/210537129/composite EYPT -0.94% , a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results and highlight recent corporate developments.

To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9257913. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com . A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals /zigman2/quotes/210537129/composite EYPT -0.94% is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert [(R)] technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert's proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ [(R)] for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia
Stern IR
Direct: (212)-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

COMTEX_406320792/2471/2022-04-27T07:00:17

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/210537129/composite
US : U.S.: Nasdaq
$ 10.50
-0.10 -0.94%
Volume: 69,706
Aug. 18, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$361.16 million
Rev. per Employee
$337,089
loading...
/zigman2/quotes/210537129/composite
US : U.S.: Nasdaq
$ 10.50
-0.10 -0.94%
Volume: 69,706
Aug. 18, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$361.16 million
Rev. per Employee
$337,089
loading...

Partner Center

Link to MarketWatch's Slice.